Selected stock price target news of the day - July 1st, 2025

By: Matthew Otto

Robinhood Launches Tokenized Equities and Blockchain Initiatives to Expand Global Crypto Access

Robinhood Markets announced a broad expansion of crypto and tokenization products across Europe during its June 30, 2025, product showcase in Cannes, France. The company has introduced over 200 U.S. stock and ETF tokens to customers in 30 EU and EEA countries.

Robinhood has introduced tokenized shares of private companies OpenAI and SpaceX, enabled by the EU’s more flexible investor eligibility rules. In connection with the launch, Robinhood is distributing $5.35 worth of OpenAI and $5.35 worth of SpaceX tokens to every eligible user who begins trading stock tokens by July 7, allocating $1 million and $500,000 worth of each token, respectively, to the campaign.

Robinhood’s strategy includes long-term infrastructure development through a new proprietary Layer 2 blockchain, built on Arbitrum, which will power real-world asset tokenization. The new chain, currently in development and expected to support 24/7 trading, self-custody, and cross-chain bridging. Currently, stock tokens are issued on Arbitrum. For more active investors, Robinhood is introducing crypto perpetual futures in the EU with up to 3x leverage, routed via Bitstamp’s perpetual futures exchange.

In the U.S., Robinhood has relaunched crypto staking—previously halted by the SEC—for Ethereum (ETH) and Solana (SOL), allowing users to earn yield by contributing to network operations. Additional features include a 1–2% instant crypto deposit boost (up to $500 million in total deposits), a crypto rewards credit card, smart exchange routing with tiered fee structures, and tax lot management for strategic selling.

Analysts Boost Price Targets on Crypto and Tokenization Growth

Keybanc analyst Alex Markgraff maintained an Overweight rating and raised the price target from $60 to $110.
Cantor Fitzgerald analyst Brett Knoblauch lifted that price target to $100.
Mizuho analyst Dan Dolev boosted the price target from $80 to $99.

Which Analyst has the best track record to show on HOOD?

Analyst Kyle Voigt (STIFEL) currently has the highest performing score on HOOD with 3/3 (100%) price target fulfillment ratio. His price targets carry an average of $-5.28 (-8.09%) potential downside. Robinhood Markets stock price reaches these price targets on average within 14 days.

INmune Bio Reports Mixed Results for Alzheimer’s Drug XPro™ in Mid-Stage Trial

INmune Bio announced findings from its Phase 2 MINDFuL clinical trial evaluating XPro™, a selective soluble TNF inhibitor, in patients with early-stage Alzheimer’s disease (AD).

According to the company, the trial enrolled 208 participants and did not meet its primary endpoint of cognitive improvement in the modified intent-to-treat (mITT) population (n=200) based on the Early Mild Alzheimer’s Cognitive Composite (EMACC) measure. However, predefined subgroup of 100 amyloid-positive patients with at least two biomarkers of inflammation showed cognitive, behavioral, and biological improvements with XPro™ treatment compared to placebo.

Reported effect sizes were 0.27 for cognitive benefit (EMACC), –0.24 for behavioral improvement (Neuropsychiatric Inventory), and –0.20 for reduced levels of pTau217, a blood-based biomarker of AD pathology.

INmune Bio reported that XPro™ was well tolerated across treatment arms. This is including in patients with two ApoE4 gene copies, a known genetic risk factor for AD. Unlike anti-amyloid drugs such as Leqembi (Eisai/Biogen) or Kisunla (Eli Lilly), no amyloid-related imaging abnormalities (ARIA-E or ARIA-H) were observed. Injection site reactions were the most common adverse event, occurring in 80% of XPro™-treated participants; 10 out of 14 patient withdrawals in the treatment group were attributed to this side effect. No deaths, hospitalizations related to the drug, or organ toxicities were reported.

The Alzheimer’s Association estimates that over 6.9 million Americans aged 65 and older are currently living with AD. INmune Bio estimates that approximately half of early-stage AD patients may exhibit inflammation-related biomarkers targeted by XPro™. Additional analyses will be presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27–31, 2025).

Analyst Downgrades Following XPro™ Results, Slashes Price Target

Scotiabank analyst George Farmer downgraded from Sector Outperform to Sector Underperform and the price target from $23 to $0.6.

Which Analyst has the best track record to show on INMB?

Analyst Mayank Mamtani (B. RILEY SECURITIES) currently has the highest performing score on INMB with 1/2 (50%) price target fulfillment ratio. His price targets carry an average of $1.52 (27.74%) potential upside. INmune Bio stock price reaches these price targets on average within 13 days.

Progress Software Beats Q2 EPS Estimates, Raises Full-Year Guidance

Progress Software reported second quarter earnings per share (EPS) of $1.4, exceeding the analyst estimate of $1.3. Revenue for the quarter rose 36% year-over-year to $237 million, slightly below the consensus estimate of $237.53 million.

Progress also reported annualized recurring revenue of $838 million, up 46% compared to the same period last year. Operating income grew 42% from the prior year, and operating margin reached 40%, a two-percentage-point improvement. Net income rose to $61.7 million, while cash flow from operations declined 42% to $37.1 million. The company ended the quarter with $102 million in cash and paid down $40 million in debt, continuing toward its full-year debt reduction target of $160 million.

For the third quarter of 2025, Progress expects EPS in the range of $1.28 to $1.34, in line with the consensus estimate of $1.3. Full-year revenue is projected to fall between $962 million and $974 million, with full-year EPS expected between $5.28 and $5.4, up from prior guidance.

Analysts Reaffirm Positive Outlook Following Q2 Results

Wedbush analyst Daniel Ives reiterated an Outperform rating and the $75 price target.
DA Davidson analyst Lucky Schreiner reiterated a Buy rating.

Which Analyst has the best track record to show on PRGS?

Analyst Fatima Boolani (CITI) currently has the highest performing score on PRGS with 3/4 (75%) price target fulfillment ratio. Her price targets carry an average of $5.06 (8.04%) potential upside. Progress Software stock price reaches these price targets on average within 163 days.